Evidence map›Paper›PMID 36186547›Full record

ArticleMolecular systems design & engineering2022

Molecular insights into Mmpl3 leads to the development of novel indole-2-carboxamides as antitubercular agents.

Rajdeep Ray, Sumit Raosaheb Birangal, Fajeelath Fathima, Helena I Boshoff, He Eun Forbes, Raghu H Chandrashekhar, Gautham G Shenoy

Open access · greenAbstract read
In one paragraph

Article in Molecular systems design & engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Rajdeep RayDepartment of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India. Pin: 576104.
Sumit Raosaheb BirangalDepartment of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India. Pin: 576104.
Fajeelath FathimaDepartment of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India. Pin: 576104.
Helena I BoshoffTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
He Eun ForbesTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Raghu H ChandrashekharDepartment of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India. Pin: 576104.
Gautham G ShenoyDepartment of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India. Pin: 576104.
Manipal Academy of Higher Education · INNational Institutes of Health · US

Funding

PATHOGENIC MECHANISMS OF MYCOBACTERIUM TUBERCULOSISZ01AI000693 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI BARRY, CLIFTON · 1993 to 2008
$8.1M
Intramural NIH HHS Z01 AI000693
6 · The paper itself

Abstract

Tuberculosis (TB) is an air-borne infectious disease and is the leading cause of death among all infectious diseases globally. The current treatment regimen for TB is overtly long and patient non-compliance often leads to drug resistant TB resulting in a need to develop new drugs that will act via novel mechanisms. In this research work, we selected

Indexed as

antitubercularindole-2-carboxamidesMmpl3molecular dynamicsstructural insights

Identifiers

PMID36186547
PMCPMC9518744
OpenAlexW4214917094

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.